Literature DB >> 9068325

Metabolic effects of i.v. propacetamol, metamizol or external cooling in critically ill febrile sedated patients.

B Poblete1, J A Romand, C Pichard, P König, P M Suter.   

Abstract

We have measured the metabolic response to sequential administration of propacetamol, metamizol and/or external cooling in 20 febrile patients under sedation and analgesia and during mechanical ventilation. There was no change in temperature (T degree) after propacetamol therapy, whereas after metamizol only a small decrease was noted (from 38.9 (SEM 0.2) to 38.5 (0.3) degrees C; P = 0.02). External cooling produced a significant decrease in T degree (39.1 (0.2) to 37.1 (0.2) degrees C; P < 0.0001) accompanied by a decrease in energy expenditure (EE) (2034 (73) to 1791 (88) kcal day-1; P < 0.004). Heart rate and minute ventilation decreased significantly in parallel. There were no other changes in haemodynamics or pulmonary gas exchanges. We conclude that propacetamol and metamizol did not produce a clinically significant decrease in T degree in febrile ICU patients whereas external cooling decreased both T degree and EE. The parallel decrease in body temperature and EE seemed to be related to opioid administration or sedation, or both.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9068325     DOI: 10.1093/bja/78.2.123

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  16 in total

Review 1.  Hypothesis: Fever control, a niche for alpha-2 agonists in the setting of septic shock and severe acute respiratory distress syndrome?

Authors:  F Petitjeans; S Leroy; C Pichot; A Geloen; M Ghignone; L Quintin
Journal:  Temperature (Austin)       Date:  2018-05-22

2.  Fever is associated with delayed ventilator liberation in acute lung injury.

Authors:  Giora Netzer; David W Dowdy; Thelma Harrington; Satish Chandolu; Victor D Dinglas; Nirav G Shah; Elizabeth Colantuoni; Pedro A Mendez-Tellez; Carl Shanholtz; Jeffrey D Hasday; Dale M Needham
Journal:  Ann Am Thorac Soc       Date:  2013-12

Review 3.  Therapeutic temperature modulation in neurocritical care.

Authors:  Neeraj Badjatia
Journal:  Curr Neurol Neurosci Rep       Date:  2006-11       Impact factor: 5.081

4.  [Antipyretic strategies for acute stroke: a nationwide survey among German stroke units].

Authors:  B Kallmünzer; A Beck; S Schwab; R Kollmar
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

Review 5.  Adjunctive drug treatment in severe hypoxic respiratory failure.

Authors:  S Elsasser; H Schächinger; W Strobel
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

6.  Respective impact of lowering body temperature and heart rate on mortality in septic shock: mediation analysis of a randomized trial.

Authors:  Frédérique Schortgen; Anaïs Charles-Nelson; Lila Bouadma; Geoffray Bizouard; Laurent Brochard; Sandrine Katsahian
Journal:  Intensive Care Med       Date:  2015-07-23       Impact factor: 17.440

7.  Acetaminophen has limited antipyretic activity in critically ill patients.

Authors:  Rachel S Greenberg; Hegang Chen; Jeffrey D Hasday
Journal:  J Crit Care       Date:  2009-09-24       Impact factor: 3.425

8.  Randomized trial of the effect of antipyresis by metamizol, propacetamol or external cooling on metabolism, hemodynamics and inflammatory response.

Authors:  Valerio Gozzoli; Miriam M Treggiari; Gian-Reto Kleger; Pascale Roux-Lombard; Marc Fathi; Claude Pichard; Jacques-André Romand
Journal:  Intensive Care Med       Date:  2004-01-13       Impact factor: 17.440

9.  Early antipyretic exposure does not increase mortality in patients with gram-negative severe sepsis: a retrospective cohort study.

Authors:  Nicholas Mohr; Lee Skrupky; Brian Fuller; Hawnwan Moy; Robert Alunday; Michael Wallendorf; Scott Micek; Richard Fagley
Journal:  Intern Emerg Med       Date:  2012-08-28       Impact factor: 3.397

10.  Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care.

Authors:  Manuela Cormio; Giuseppe Citerio
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.